2016
DOI: 10.1016/j.clinre.2015.06.014
|View full text |Cite
|
Sign up to set email alerts
|

Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 34 publications
0
4
0
Order By: Relevance
“… 3 HP infection is a major pathogenic factor of PU and chronic gastritis in children. 4 Through the investigation, HP infection rate for children is 10%~80%. 5…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“… 3 HP infection is a major pathogenic factor of PU and chronic gastritis in children. 4 Through the investigation, HP infection rate for children is 10%~80%. 5…”
Section: Introductionmentioning
confidence: 99%
“…3 HP infection is a major pathogenic factor of PU and chronic gastritis in children. 4 Through the investigation, HP infection rate for children is 10%~80%. 5 At present, the conventional triple therapy proton pump inhibitor (PPI) + amoxicillin + clarithromycin are mostly adopted clinically.…”
Section: Introductionmentioning
confidence: 99%
“…Although an eradication rate of over 90% is still being achieved with seven-day triple therapy options for H. pylori infection in regions with low antibiotic resistance, [ 15 ] the eradication rate has been reduced to below 80% in regions with the problem of antibiotic resistance [ 14 ]. Alternative methods of first-line therapy such as increasing drug dose [ 16 ], prolonging treatment period [ 17 ], sequential administration of drugs [ 18 ], or using different drug combinations [ 19 21 ] have emerged to achieve a successful eradication.…”
Section: Discussionmentioning
confidence: 99%
“…Most of the compounds from these groups are heteroleptic organometallic complexes, including oxoclasters. A great advantage of the use of bismuth-based drugs is the lack of H. pylori resistance towards these drugs [22,41,[79][80][81]. These studies inspired us to examine the antimicrobial properties of new polymeric Bi(III) complexes with low-molecular weight N-heteroaromatic carboxylic acids against Helicobacter pylori.…”
Section: Antibacterial Activity Towards Helicobacter Pylorimentioning
confidence: 99%